The more complete inhibition of PD-1/PD-L1/PD-L2 pathways offered by the combination of PD-1 and PD-L1 inhibitors may elicit a stronger anti-tumour effect than inhibition of single components of the pathway alone, and warrants investigation. This evidence concerns the gene PDCD1 and neoplasm.